Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 3% Improvement Relative Risk Ivermectin  Ravikirti et al.  LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Retrospective 965 patients in India (April - May 2021) Multiple issues, see notes Ravikirti et al., Research Square, Apr 2022 Favors ivermectin Favors control

Association between Ivermectin treatment and mortality in Covid-19: A hospital-based case-control study

Ravikirti et al., Research Square, doi:10.21203/
Apr 2022  
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 100 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 965 late stage (44% severe, 27% ICU) hospitalized patients in India, showing no significant difference with ivermectin treatment. Overall mortality was very high, suggesting very late treatment. The low non-weight-adjusted dose may not be very effective with such late stage patients. 210 patients were excluded due to early discharge, which may have been patients with earlier onset that are more likely to benefit with ivermectin. Age grouping is very unusual with no breakdown of ages for the 71% of patients >45. Numbers may be unreliable, e.g., cardiovascular disease counts and/or percentages for IVM appear incorrect. Details of adjustments are not provided, there may be extreme confounding by age within the >45 groups which contain the majority of the patients, in addition to confounding by indication.
This is the 82nd of 100 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion). 47 studies are RCTs, which show efficacy with p=0.0000002.
This study is excluded in the after exclusion results of meta analysis: exclusion of patients in less severe condition, data/analysis concerns.
risk of death, 2.8% lower, RR 0.97, p = 0.82, treatment 53 of 171 (31.0%), control 254 of 794 (32.0%), NNT 100, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ravikirti et al., 6 Apr 2022, retrospective, India, preprint, 7 authors, study period 1 April, 2021 - 15 May, 2021, dosage varies.
This PaperIvermectinAll
Association between Ivermectin treatment and mortality in Covid-19: A hospital-based case-control study
Ravikirti, Alok Ranjan, Rajdeep Porel, Ketan Agarwal, S M Tahaseen, Shyama, Anjani Kumar
Introduction : This study was designed to test the hypothesis that exposure to ivermectin in early disease prevents mortality due to COVID-19. A secondary objective was to see if the drug has any impact on the length of hospital stay among the survivors. Methods It was a hospital-based retrospective case control Study conducted at a tertiary teaching hospital in India. All patients with a diagnosis of COVID-19 who were admitted between 1st April and 15th May 2021 and received inpatient care were included. Important variables like demographic details, dates of admission and discharge or death, symptoms at the time of admission, comorbidities, severity of illness at the time of admission, whether ivermectin was administered or not during the course of the illness and other treatments received as part of the standard of care were retrieved from the medical records. Results Of the 965 patients who received inpatient care, 307 died during their hospital stay while 658 were successfully discharged. The proportion of cases treated with ivermectin was 17.26% among the nonsurvivors (53/307) and 17.93% among the survivors (118/658). The effect was statistically insigni cant (crude OR = 0.954 ;95% CI: 0.668-1.364, p = 0.80). Among the survivors, the median length of stay was 11 days for patients who received ivermectin (IQR: 7-15) as well as for those who did not (IQR 7-16). Conclusion This study did not show any effect of ivermectin on in-patient mortality in patients with COVID-19 and there was no effect of the drug on the length of hospital stay among the survivors.
Declarations Authorship Statement: All authors meet the ICMJE authorship criteria. Con icts of interest: None Funding: None
Abdulamir, Ahmed, Asghar, Hill, Preliminary meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
Ahmed, Karim, A ve day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11
Alam, Murshed, A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline, J Bangladesh Coll Phys Surg, doi:10.3329/jbcps.v38i0.47512
Babalola, Bode, Ajayi, Ivermectin shows clinical bene ts in mild to moderate COVID19: a randomised controlled double-blind, dose-response study in Lagos, QJM-Int J Med, doi:10.1093/qjmed/hcab035
Bryant, Lawrie, Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, Am J Ther, doi:10.1097/MJT.0000000000001402
Caly, Druce, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Research, doi:10.1016/j.antiviral.2020.104787
Camprubi, Almuedo-Riera, Lack of e cacy of standard doses of ivermectin in severe COVID-19 patients, PLoS ONE, doi:10.1371/journal.pone.0242184
Chowdhury, Shahbaz, Karim, A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients, EJMO
Espitia-Hernandez, Munguia, Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study, Biomedical Research
Gonzalez, Gámez, Enciso, E cacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial, medRxiv
Guzzo, Furtek, Porras, Chen, Tipping et al., Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol, doi:10.1177/009127002401382731
Hashim, Maulood, Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq, doi:10.1101/2020.10.26.20219345
Hector, Roberto, Safety and E cacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19 -The I.D.E.A. Protocol, Journal of Clinical Trials
Hill, Mirchandani, Pilkington, Ivermectin for COVID-19: Addressing potential bias and medical fraud, Open Forum Infectious Diseases
Karale, Bansal, Makadia, A Meta-analysis of Mortality, Need for ICU admission, Use of Mechanical Ventilation and Adverse Effects with Ivermectin Use in COVID-19 Patients, medRxiv, doi:10.1101/2021.04.30.21256415
Khan, Khan, Ivermectin treatment may improve the prognosis of patients with COVID-19, Archivos de Bronconeumologia
Lamontagne, Agoritsas, Macdonald, A living WHO guideline on drugs for covid-19, BMJ2020, doi:10.1136/bmj.m3379
Lim, Hor, Tay, Effect of Ivermectin on Disease Progression among Adults with Mild to Moderate COVID-19 and Comorbidities, JAMA Intern Med. Published online, doi:10.1001/jamainternmed.2022.0189
López-Medina, López, Hurtado, Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2021.3071
Mahmud, Rahman, Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, J Int Med Res, doi:10.1177/03000605211013550
Mohan, Tiwari, Suri, Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial, J Infect Chemother, doi:10.1016/j.jiac.2021.08.021
Niaee, Namdar, Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial, Asian Pac J Trop Med
Peña-Silva, Duffull, Steer, Jaramillo-Rincon, Gwee et al., Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19, Br J Clin Pharmacol
Rajter, Sherman, Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019 -The ICON Study
Ravikirti, Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India, J Pharm Pharm Sci, doi:10.18433/jpps32105
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop